xl-652
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00836602)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LXR-betaAGONIST
NR1H2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1- Mol. weight
- 509.07 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545418 ↗
- ChEMBLCHEMBL3360975 ↗
Also known as
- 2-(2-(1-(2-chlorophenyl)-1-methylethyl)-1-(3'-(methylsulfonyl)-4-biphenylyl)-1h-imidazol-4-yl)-2-propanol
- bms-779788
- bms-779788
- bms-779788
- bms-779788
- exel-04286652
- xl-014
- xl-652
- xl-652
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00836602 | Phase 1 | Feb 1, 2009 | Bristol-Myers Squibb |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1